Survodutide Reference

Plain English

What it is

Survodutide is an experimental medicine still being tested in research, not an approved drug. It is a 'dual agonist,' meaning it switches on two of the body's appetite and metabolism signals at once (the GLP-1 hormone pathway and the glucagon pathway). Because regulators have not approved it, it has no brand name and is only legally available inside clinical trials, so anything sold online claiming to be survodutide is not the studied drug.

What people use it for

In trials it is being studied in adults who have obesity or are overweight, and in people with a liver condition called MASH (a buildup of fat, inflammation, and scarring in the liver). In the peptide and GLP-1 community it draws interest as a newer dual-agonist that researchers hope could help with weight loss, but it is not an approved treatment for anyone.

What the science shows

The evidence comes from human studies but is still mid-to-late stage. A mid-stage (Phase 2) trial published in a major medical journal found it improved MASH more than a placebo (an inactive dummy treatment) without making liver scarring worse. A later-stage (Phase 3) obesity study reported, in company announcements, clearly more weight loss than placebo, with the most common side effects being stomach-related (nausea, vomiting, and diarrhea).

The catch

It is still experimental and not approved by the FDA or other regulators, so its long-term safety and real-world benefits are not yet confirmed and the large liver-disease trials are still running. The headline weight-loss numbers so far come from the company that makes it rather than from a full published study or a regulator. Products sold online as survodutide are not the trial drug, are not quality-checked, and could be unsafe.

Reference summary

Phase 2 MASH/MASH-fibrosis trial (Sanyal 2024 NEJM, n=293 adults with biopsy-confirmed MASH, 48 weeks) reported MASH improvement in 47 to 62 percent of survodutide groups (for example 62 percent at the 4.8 mg dose and 43 percent at 6.0 mg) versus 14 percent on placebo, with concurrent reduction in liver fat and improvement in fibrosis biomarkers. The Phase 3 SYNCHRONIZE-1 obesity trial reported positive sponsor topline on April 28, 2026 (up to 16.6 percent mean weight loss at 76 weeks versus 3.2 percent on placebo); the LIVERAGE and LIVERAGE-Cirrhosis Phase 3 MASH trials are ongoing with readouts expected later in 2026. Common adverse events were dose-dependent gastrointestinal (nausea, vomiting, diarrhea).

Regulatory and posture

Categories

GLP-1, Fat Loss

Aliases

BI 456906, GLP-1 / glucagon dual receptor agonist

Evidence posture

human - Phase 2 MASH data are published and the Phase 3 SYNCHRONIZE-1 obesity trial reported positive topline in April 2026; the Phase 3 MASH program is ongoing. Survodutide remains investigational.

Regulatory status

Investigational. Survodutide is a GLP-1 / glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma; the Phase 3 SYNCHRONIZE program covers obesity and the LIVERAGE program covers MASH / MASH-fibrosis. The Phase 3 SYNCHRONIZE-1 obesity trial reported positive topline in April 2026. There is no FDA-approved drug label, and survodutide is not on FDA's approved bulk-substances list for compounding.

Content review status

investigational verified

Related tools

• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
• Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.